Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/15/2024 | Mkt Perform → Outperform | William Blair | |
| 8/8/2023 | $15.00 → $8.00 | Overweight → Neutral | JP Morgan |
| 7/14/2023 | Buy → Hold | Needham | |
| 1/17/2023 | Outperform → Mkt Perform | William Blair | |
| 12/9/2021 | $47.00 | Hold → Buy | Needham |
| 11/8/2021 | $70.00 → $40.00 | Hold | Stifel |
| 11/5/2021 | $72.00 → $42.00 | Market Perform | SVB Leerink |
| 11/2/2021 | $71.00 → $45.00 | Underweight → Neutral | JP Morgan |
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 24th Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website,
William Blair upgraded Inogen from Mkt Perform to Outperform
JP Morgan downgraded Inogen from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously
Needham downgraded Inogen from Buy to Hold
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
10-Q - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
DEFA14A - Inogen Inc (0001294133) (Filer)
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer. Kevin Smith, President and Chief Executive Officer of Inogen said, "We are excited to welcome Eric to the Inogen team. With over 20 years of experience driving growth and leading high-performing teams in the respiratory care business, his leadership will be instrumental as we expand our product offerings and solutions for patients with respiratory conditions in the Uni
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo
Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% Company Provides 2025 Growth Outlook Recently Announced Strategic Collaboration with Yuwell to Expand Product Portfolio, Global Reach Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024. "2024 was a stellar year for Inogen. With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, President and Ch
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)